Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03107663 · ClinicalTrials.gov registry record · Phase 1
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
A Phase 1 study, sponsored by ImaginAb.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03107663 is a Phase 1 study that has completed, run by ImaginAb. The registered enrollment target is 15 participants.
The verdict
NCT03107663, a Phase 1 study, has completed, sponsored by ImaginAb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to determine imaging parameters for optimal lymphoid and tumor visualization.
Interventions
- DRUG ⁸⁹Zr-Df-IAB22M2C Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-06-19 |
| Est. Completion | 2018-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03107663
The ClinicalTrials.gov registry entry for NCT03107663 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImaginAb, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ⁸⁹Zr-Df-IAB22M2C Infusion is the first listed.
NCT03107663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03107663 about?
NCT03107663 is a clinical study titled "⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma". To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to determine imaging parameters for optimal lymphoid and tumor visualization.
What is the current status of trial NCT03107663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-06-19. Estimated completion is 2018-08-16.
What interventions are being tested in trial NCT03107663?
The interventions under investigation include: ⁸⁹Zr-Df-IAB22M2C Infusion (DRUG).
Who is sponsoring clinical trial NCT03107663?
This trial is sponsored by ImaginAb, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.